ストックスクリーナーアプリを入手
3.7035
9.19%
-0.3765
前日終値:
$4.08
開ける：
$4.07
24時間の取引高:
2.13M
Relative Volume:
1.20
時価総額：
$394.22M
収益：
$42.51M
当期純損益:
$-116.49M
株価収益率:
-3.0607
EPS:
-1.21
ネットキャッシュフロー:
$-120.82M
1週間 パフォーマンス:
-5.48%
1か月 パフォーマンス:
-48.18%
6か月 パフォーマンス:
-50.40%
1年 パフォーマンス:
-50.20%
1日の値動き範囲:
$3.58
$4.22
1週間の範囲:
$3.54
$4.22
52週間の値動き範囲:
$2.70
$13.01
Tango Therapeutics Inc Stock (TNGX) Company Profile
TNGX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| TNGX | 3.70 | 394.22M | 42.51M | -116.49M | -120.82M | -1.21 |
| VRTX | 449.47 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 749.23 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.07 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.16 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.06 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-12-08 | 開始されました | B. Riley Securities | Buy |
| 2022-10-20 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | 開始されました | SVB Leerink | Outperform |
Tango Therapeutics Inc (TNGX) 最新ニュース
Tango Therapeutics director Mace Rothenberg acquires $74,000 in stock By Investing.com - Investing.com Canada
Tango Therapeutics director Mace Rothenberg acquires $74,000 in stock - Investing.com
Trv Gp Iv LLC Cuts Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) - MarketBeat
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Average Recommendation of "Buy" by Analysts - MarketBeat
B. Riley Increases Earnings Estimates for Tango Therapeutics - Defense World
B. Riley Forecasts Higher Earnings for Tango Therapeutics - MarketBeat
B. Riley Cuts Tango Therapeutics (NASDAQ:TNGX) Price Target to $8.00 - Defense World
Tango Therapeutics' SWOT analysis: stock outlook amid PRMT5 inhibitor progress - Investing.com
Tango Therapeutics (NASDAQ:TNGX) Earns “Buy” Rating from HC Wainwright - Defense World
The Analyst Landscape: 5 Takes On Tango Therapeutics - Benzinga
B. Riley Has Lowered Expectations for Tango Therapeutics (NASDAQ:TNGX) Stock Price - MarketBeat
FY2024 Earnings Forecast for TNGX Issued By Leerink Partnrs - Defense World
Leerink Partnrs Brokers Increase Earnings Estimates for TNGX - MarketBeat
EcoR1 Capital sells $8.4 million in Tango Therapeutics stock - Investing.com India
EcoR1 Capital sells $8.4 million in Tango Therapeutics stock By Investing.com - Investing.com Australia
Tango Therapeutics' (TNGX) Buy Rating Reiterated at HC Wainwright - MarketBeat
Wedbush Has Pessimistic Outlook of TNGX FY2024 Earnings - Defense World
EcoR1 Capital, LLC Adjusts Stake in Tango Therapeutics Inc - GuruFocus.com
Wedbush Forecasts Reduced Earnings for Tango Therapeutics - MarketBeat
Tango Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Tango Therapeutics sees $9.67m stock sale by Boxer Capital - Investing.com India
Tango Therapeutics (NASDAQ:TNGX) Price Target Lowered to $8.00 at Guggenheim - MarketBeat
Tango Therapeutics Advances Cancer Treatment Pipeline - TipRanks
Two to Tango: Brain cancer drugs go further into development - BioWorld Online
Tango stock plunges 28% amid pipeline updates, Q3 earnings report (NASDAQ:TNGX) - Seeking Alpha
U.S. Stock market: Sunnova energy(-42.35%0, Zoomcar(-38.48%), Tango therapeutics(-27.22%) among stock losers during early trading - Business Upturn
Tango Shares Plunge After 3Q Loss, Product Plans - MarketWatch
Tango Therapeutics advances cancer drug into full development By Investing.com - Investing.com Canada
Tango Therapeutics, Inc. (TNGX) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program - BioSpace
Tango Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Tango Therapeutics advances cancer drug into full development - Investing.com
Tango Therapeutics Reports 43% Response Rate in Cancer Trial, Secures $293M Cash Runway | TNGX Stock News - StockTitan
(TNGX) On The My Stocks Page - Stock Traders Daily
Tango Therapeutics (NASDAQ:TNGX) Hits New 52-Week LowTime to Sell? - MarketBeat
Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio - Simply Wall St
Tango Therapeutics (NASDAQ:TNGX) Stock Rating Reaffirmed by HC Wainwright - Defense World
Tango Therapeutics (NASDAQ:TNGX) Sets New 12-Month Low After Insider Selling - Defense World
Tango Therapeutics (NASDAQ:TNGX) Reaches New 12-Month Low Following Insider Selling - MarketBeat
Tango Therapeutics (NASDAQ:TNGX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Tango Therapeutics target held at $13 by H.C. Wainwright - Investing.com
Tango Therapeutics (NASDAQ:TNGX) Sees Strong Trading VolumeHere's Why - MarketBeat
Short Interest in Tango Therapeutics, Inc. (NASDAQ:TNGX) Decreases By 17.7% - MarketBeat
Tango Therapeutics, Inc. (NASDAQ:TNGX) Insider Sells $4,348,710.00 in Stock - MarketBeat
Tango Therapeutics (NASDAQ:TNGX) Receives Buy Rating from HC Wainwright - MarketBeat
Tango Therapeutics sees $4.3 million stock sale by Boxer Capital - Investing.com Australia
Tango Therapeutics (NASDAQ:TNGX) Stock Price Up 8.7%Time to Buy? - MarketBeat
Tango Therapeutics sees $6.1 million stock sale by Boxer Capital - Investing.com Australia
(TNGX) Proactive Strategies - Stock Traders Daily
Tango Therapeutics, Inc. (NASDAQ:TNGX) Insider Boxer Capital Management, Llc Sells 625,000 Shares - MarketBeat
Tango Therapeutics (NASDAQ:TNGX) Hits New 1-Year LowHere's What Happened - MarketBeat
Tango Therapeutics Inc (TNGX) 財務データ
収益
当期純利益
現金流量
EPS
1.80%
0.42%
大文字化:
|
ボリューム (24 時間):